Nektar Therapeutics (NASDAQ:NKTR) Director Robert Chess sold 6,400 shares of the company’s stock in a transaction dated Thursday, September 21st. The shares were sold at an average price of $21.72, for a total transaction of $139,008.00. Following the transaction, the director now owns 274,223 shares in the company, valued at $5,956,123.56. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.04). The company had revenue of $34.60 million during the quarter, compared to analysts’ expectations of $33.64 million. Nektar Therapeutics had a negative net margin of 157.14% and a negative return on equity of 1,223.34%. Nektar Therapeutics’s revenue was up 5.5% on a year-over-year basis. During the same period last year, the firm posted ($0.36) earnings per share.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/insider-selling-nektar-therapeutics-nktr-director-sells-6400-shares-of-stock/1587685.html.

Several equities analysts recently commented on NKTR shares. BidaskClub upgraded shares of Nektar Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 17th. HC Wainwright started coverage on shares of Nektar Therapeutics in a report on Monday, August 7th. They set a “buy” rating and a $31.00 price target on the stock. William Blair reiterated an “outperform” rating on shares of Nektar Therapeutics in a report on Monday, June 26th. Jefferies Group LLC reiterated a “buy” rating and set a $23.00 price target on shares of Nektar Therapeutics in a report on Friday, August 18th. Finally, ValuEngine upgraded shares of Nektar Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, September 1st. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $26.10.

Several institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. raised its stake in shares of Nektar Therapeutics by 0.9% in the 2nd quarter. BlackRock Inc. now owns 20,221,479 shares of the biopharmaceutical company’s stock valued at $395,330,000 after acquiring an additional 185,933 shares during the period. Vanguard Group Inc. raised its stake in shares of Nektar Therapeutics by 3.0% in the 2nd quarter. Vanguard Group Inc. now owns 14,009,894 shares of the biopharmaceutical company’s stock valued at $273,893,000 after acquiring an additional 401,914 shares during the period. State Street Corp raised its stake in shares of Nektar Therapeutics by 11.3% in the 2nd quarter. State Street Corp now owns 4,408,270 shares of the biopharmaceutical company’s stock valued at $86,179,000 after acquiring an additional 447,023 shares during the period. Bank of New York Mellon Corp raised its stake in shares of Nektar Therapeutics by 0.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 2,138,632 shares of the biopharmaceutical company’s stock valued at $41,812,000 after acquiring an additional 12,730 shares during the period. Finally, FMR LLC raised its stake in shares of Nektar Therapeutics by 42.4% in the 1st quarter. FMR LLC now owns 1,947,644 shares of the biopharmaceutical company’s stock valued at $45,711,000 after acquiring an additional 580,341 shares during the period. 95.08% of the stock is currently owned by institutional investors and hedge funds.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Insider Buying and Selling by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.